Sydney Australia, 24 March 2017: Benitec Biopharma Limited Advices that it has received a $5,590,225 cash refund under the Federal Government’s R&D Tax Incentive Scheme. The refund relates to the costs of research and development which qualify as eligible R&D expenditure under the Federal Government’s Scheme. The funds will be used to advance Benitec’s human therapeutic programs in gene silencing.
